Neuroscience Drug Development Europe 2023

This in-depth 2 day event will detail the journey of neuroscience discovery from initial lead through to clinical trials, bringing together leading companies for discussion, knowledge- sharing and focused networking.

Track 1: Therapeutic Strategies, Enabling Technologies & Biomarker Development 

• Advancements and emerging trends in the application of technology in developing neurological treatments 
• Neuroscience biomarker development 
• Translational approaches for drug discovery 
• Opportunities and challenges of designing and implementing targeted diagnostics and therapeutics 
• Diagnostic tool development
   

Track 2: Drug Discovery for Neurodegenerative Diseases 

• Target identification and validation approaches 
• Stem cell technology to fuel drug discovery 
• iPS cells for disease modelling and drug discovery 

• Blood brain barrier in CNS drug discovery 
• Assay Development & Screening 
• In vitro and in vivo disease modelling 
• The role of informatics in CNS drug discovery 

Sebastien Gillotin - Associate Principal Scientist at MSD

Pekka Kallunki - Principal Scientist at Lundbeck

Iain Chessell - Global head of Neuroscience at AstraZeneca

Ludovic Colin - Section Leader Neuroimmunology at Roche

Magnus Walter - Senior Director Drug Discovery, Medicinal Chemistry and Screening Biology at AbbVie

Jenny Barnett - Chief Executive Officer at Monument Therapeutics